Chronic Sinusitis, Ethmoidal Clinical Trial
A Phase II, Open-label, Two-part, Randomized, Parallel-group Trial to Evaluation the Safety, Tolerability, and Pharmacokinetics of LYR-220 in Chronic Rhinosinusitis (CRS) Patients Who Have Had a Prior Ethmoidectomy
This study will assess the safety, tolerability, and pharmacokinetics of two LYR-220 designs in symptomatic adult chronic rhinosinusitis (CRS) subjects who have had a prior bilateral total ethmoidectomy.
LYR-220 is a combination product comprised of a drug matrix, which contains the anti-inflammatory medication mometasone furoate (MF) pre-loaded in a single use applicator. LYR-220 is intended to be placed bilaterally into the sino-nasal passages by an otolaryngologist. Once in place, each LYR-220 drug matrix is designed to gradually deliver sustained topical doses of MF to the inflamed mucosal sinus tissue over 24 weeks. ;
|Status||Not yet recruiting|
|Start date||November 2021|
|Completion date||December 2022|